Latest news with #HepatitisD
Globe and Mail
2 days ago
- Business
- Globe and Mail
Hepatitis D Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Hepatitis D Pipeline Insight, 2025 ' report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Hepatitis D pipeline landscape. It covers the Hepatitis D pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatitis D pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Hepatitis D Pipeline. Dive into DelveInsight's comprehensive report today! @ Hepatitis D Pipeline Outlook Key Takeaways from the Hepatitis D Pipeline Report In June 2025, Ribocure Pharmaceuticals AB announced clinical trial is to learn if drug RBD1016 works to treat chronic hepatitis D virus infection in adults. It will also learn about the safety of drug RBD1016. There will be 2 treatment groups - an active group (n=10) and a deferred active group (n=5), with participants allocated randomly. In the active group, participants will receive RBD1016. In the deferred active group, participants will receive 4 doses of placebo followed by deferred treatment with doses of RBD1016. In June 2025, Vir Biotechnology Inc. conducted Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment. DelveInsight's Hepatitis D Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Hepatitis D treatment. The leading Hepatitis D Companies such as Vir Biotechnology, Inc./Alnylam Pharmaceuticals, Bluejay Therapeutics, Inc., Ribocure Pharmaceuticals AB, Assembly Biosciences, Shanghai HEP Pharmaceutical Co., Ltd., Huahui Health and others. Promising Hepatitis D Pipeline Therapies such as Brelovitug 300 mg, lonafarnib, Ritonavir, Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa), hepalatide, Peginterferon Lambda-1a and others. Stay ahead with the most recent pipeline outlook for Hepatitis D. Get insights into clinical trials, emerging therapies, and leading companies with Hepatitis D @ Hepatitis D Treatment Drugs Hepatitis D Emerging Drugs Profile Tobevibart + Elebsiran: Vir Biotechnology/ Alnylam Pharmaceuticals Tobevibart is an investigational broadly neutralizing monoclonal antibody targeting the hepatitis B surface antigen. It is designed to inhibit the entry of hepatitis B and hepatitis delta viruses into hepatocytes, and to reduce the level of circulating viral and subviral particles in the blood. Tobevibart, which incorporates Xencor's Xtend™ and other Fc technologies, has been engineered to have an extended half-life and was identified using Vir Biotechnology's proprietary monoclonal antibody discovery platform. Elebsiran is an investigational hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) designed to degrade hepatitis B virus RNA transcripts and limit the production of hepatitis B surface antigen. Current data indicates that it has the potential to have direct antiviral activity against hepatitis B virus and hepatitis delta virus. It is the first asset in Vir Biotechnology's collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical studies. Currently, this combination drug product is in Phase III stage of its development for the treatment of Hepatitis D. Brelovitug: Bluejay Therapeutics Brelovitug is an investigational, highly potent, pan-genotypic, fully human IgG1 mAb that targets the anti-HBsAg on both the HDV and the HBV. Brelovitug is designed to neutralize and remove hepatitis B and hepatitis D virions and deplete HBsAg-containing subviral particles, which gives brelovitug a potentially advantageous safety profile and makes it a potentially efficacious treatment for CHD, a condition with urgent unmet medical need. In addition, brelovitug has shown immunomodulatory functions in CHB patients, which may help to reconstitute antiviral immunity and contribute to functional cure for CHB when combined with other agents. Currently, the drug is in the Phase II/III stage of its development for the treatment of Hepatitis D. RBD1016: Ribocure Pharmaceuticals AB RBD1016 is a GalNAc-siRNA drug independently developed by Ribo based on its proprietary GalNAc-siRNA platform, targeting the X gene of hepatitis B virus. It inhibits all four HBV transcripts through the RNA interference mechanism, and can simultaneously inhibit HBV DNA replication, reduce cccDNA and integrate DNA derived HBsAg and other antigens. RBD1016 demonstrates well-tolerated safety profile in Phase I study including both healthy subjects and patients with CHB infection. RBD1016 shows a highly efficient long-acting effect of reducing the HBsAg in patients. Currently, the drug is in Phase II stage of its development for the treatment of Hepatitis D. The Hepatitis D Pipeline Report Provides Insights into- The report provides detailed insights about companies that are developing therapies for the treatment of Hepatitis D with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatitis D Treatment. Hepatitis D Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Hepatitis D Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hepatitis D market Explore groundbreaking therapies and clinical trials in the Hepatitis D Pipeline. Access DelveInsight's detailed report now! @ New Hepatitis D Drugs Hepatitis D Companies Vir Biotechnology, Inc./Alnylam Pharmaceuticals, Bluejay Therapeutics, Inc., Ribocure Pharmaceuticals AB, Assembly Biosciences, Shanghai HEP Pharmaceutical Co., Ltd., Huahui Health and others. Hepatitis D pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Hepatitis D Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Hepatitis D Treatment. Learn about new drugs, Hepatitis D Pipeline developments, and key companies with DelveInsight's expert analysis @ Hepatitis D Market Drivers and Barriers Scope of the Hepatitis D Pipeline Report Coverage- Global Hepatitis D Companies- Vir Biotechnology, Inc./Alnylam Pharmaceuticals, Bluejay Therapeutics, Inc., Ribocure Pharmaceuticals AB, Assembly Biosciences, Shanghai HEP Pharmaceutical Co., Ltd., Huahui Health and others. Hepatitis D Pipeline Therapies- Brelovitug 300 mg, lonafarnib, Ritonavir, Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa), hepalatide, Peginterferon Lambda-1a and others. Hepatitis D Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Hepatitis D Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Hepatitis D Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Hepatitis D Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Hepatitis D: Overview Pipeline Therapeutics Therapeutic Assessment Hepatitis D– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Tobevibart + Elebsiran: Vir Biotechnology/ Alnylam Pharmaceuticals Drug profiles in the detailed report….. Mid Stage Products (Phase II/III) Brelovitug: Bluejay Therapeutics Drug profiles in the detailed report….. Early Stage Products (Phase I) Drug Name: Company Name Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Hepatitis D Key Companies Hepatitis D Key Products Hepatitis D- Unmet Needs Hepatitis D- Market Drivers and Barriers Hepatitis D- Future Perspectives and Conclusion Hepatitis D Analyst Views Hepatitis D Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Miami Herald
06-05-2025
- Health
- Miami Herald
Global Survey Reveals Urgent Gaps in Awareness, Access, and Treatment for Hepatitis D
Press Releases Global Survey Reveals Urgent Gaps in Awareness, Access, and Treatment for Hepatitis D A new report released today by the World Hepatitis Alliance (WHA) reveals widespread knowledge gaps, inequities in access, and critical systemic barriers impeding the global fight against hepatitis delta. Also known as hepatitis D, hepatitis delta is a severe liver disease affecting an estimated 12 million people worldwide. It occurs in people living with hepatitis B, leads to faster disease progression, and significantly increases the risk of liver cancer and death. The Hepatitis Delta Global Landscape Survey collected responses from 583 individuals across 102 countries, providing the most comprehensive picture to date of global stakeholder perspectives on awareness, testing, and treatment access around hepatitis delta. Key Findings: There are pronounced regional variations in reported availability and accessibility of hepatitis delta testing and treatment. Even where hepatitis delta testing and treatment are reported to be available, accessibility remains a significant challenge. Both direct and indirect costs are reported as considerable barriers to equitable access to hepatitis delta treatment and care. There are pronounced gaps in knowledge and awareness of hepatitis delta reported by all stakeholders with pronounced regional variations. Lack of knowledge is reported as the most common barrier to both testing and treatment. A third of respondents did not feel sufficiently informed to identify the barriers to hepatitis delta testing and treatment. HCPs reported low levels of training around hepatitis delta, and most expressed a clear interest in further education. "These findings highlight an urgent need for coordinated action to scale up hepatitis delta education, diagnosis, and care," said Cary James, CEO of WHA. "Without informed providers, empowered communities, and accessible health services, millions will remain undiagnosed and untreated." Calls to Action: Increase both availability and accessibility of testing and treatment for hepatitis delta in health systems. Address the issues of direct and indirect costs of testing and treatment to increase engagement by communities. Adopt testing policies to follow WHO recommendations on reflex testing for hepatitis delta. Inform people living with hepatitis B of the need to test for hepatitis delta through culturally competent awareness campaigns. Provide more robust training on hepatitis delta to healthcare professionals throughout their career progression. Increase provision of knowledge and awareness programmes for community-based organisations and policymakers. Implement skills-building programmes for community-based organisations so they can better advocate to policymakers and public health officials for greater access to testing, treatment and care. Download the full report: Note to Editors: For further information or interview requests contact: Cary James, Chief Executive, World Hepatitis Alliance Email: contact@ About WHA: The World Hepatitis Alliance is an international network of 400 civil society and community organisations across more than 100 countries. It is dedicated to harnessing the power of people living with viral hepatitis to drive its elimination. At WHA, member organisations are the cornerstone of the alliance, working collaboratively to combat hepatitis through advocacy, capacity building, and awareness-raising efforts. WHA also holds countries accountable to their commitments to elimination, fostering action by partnering with a diverse range of organisations worldwide, from local civil society groups to ministries of health and global institutions. SOURCE: World Hepatitis Alliance This story was originally published May 6, 2025 at 8:06 AM.
Los Angeles Times
09-04-2025
- Health
- Los Angeles Times
Alcoholic Cirrhosis: Key Facts and Treatment Insights
Alcoholic cirrhosis is a serious health condition that develops as a result of alcohol related liver disease, which occurs after a person has consumed large amounts of alcohol for a long period of time. When this happens, the liver becomes permanently scarred and can no longer keep up with many of its normal duties, like removing harmful substances from the body or making the proteins and nutrients we need. Below is a look at how alcoholic cirrhosis forms, what symptoms it can cause, and why it's important to seek help if you or someone you know might be affected by it. Alcoholic cirrhosis is the last and most severe stage of a group of diseases called alcohol-associated liver disease (ALD). Alcoholic cirrhosis is a severe form of chronic liver disease that results from prolonged alcohol abuse, though different from Alcohol Hepatitis and others like Hepatitis B, Hepatitis C, Hepatitis D and Hepatitis E. Think of the liver as a filter in your body that breaks down what you eat and drink. When there is too much alcohol over many years, this filter becomes damaged. The damage eventually turns healthy liver tissue into scarred tissue, also known as fibrosis. At that point, the liver can't fix itself completely, and its ability to do vital tasks—like cleaning the blood and helping with digestion—slows down or stops. Heavy drinking is harmful because alcohol is toxic to liver cells. Over time, these cells get inflamed and injured, leading to the formation of scar tissue. The body tries to repair them, but when that process happens over and over, it leads to scarring instead of healthy regrowth. This scarring (cirrhosis) can cause: In the beginning stages, you might not notice that something is wrong. But as cirrhosis gets worse, common signs can include: Doctors look at a person's history of alcohol use, check their body for signs of liver problems, and order tests to be sure. Blood tests can measure enzymes and other markers that show how well the liver is working. Imaging scans like ultrasounds, CTs, or MRIs allow a closer look at the liver's size and structure. Sometimes, doctors do a liver biopsy to confirm cirrhosis or to rule out other diseases such as autoimmune hepatitis that might resemble alcohol-related damage ([1]). Cirrhosis is permanent, but there are ways to keep it from getting worse and to handle any problems that come up. In cases of end stage liver disease, where the liver is severely damaged, a liver transplant may be the only viable treatment option. Stop Drinking Alcohol Entirely: This is the single most important step. Quitting alcohol may improve liver function if cirrhosis is not too advanced, and it will definitely help protect whatever healthy liver tissue remains. Medical Treatments If someone completely stops drinking, there's a possibility that the damage will not get worse, and they may live a relatively stable life. But, if the person keeps drinking, cirrhosis can quickly lead to deadly complications like total liver failure. In advanced cases, problems such as liver cancer or severe bleeding may cause life-threatening conditions. In advanced cases, complications such as kidney failure can also arise due to the interconnected nature of liver and kidney functions. Researchers are exploring medications that could help slow or even reverse some of the harm caused by alcohol. They're also looking into better methods for spotting cirrhosis before it gets too serious ([1]). Early detection and prompt treatment are crucial, since it may spare someone from needing a liver transplant or facing severe complications down the road. Alcoholic cirrhosis isn't something that appears overnight. It is the tragic result of long-term alcohol use that scars and weakens the liver, stopping it from doing vital tasks. The progression of alcoholic cirrhosis can be categorized into different stages, with each stage liver disease requiring specific management and treatment strategies. The most effective way to prevent cirrhosis from progressing is to stop drinking completely. With proper medical care and support for alcohol use disorder, people with cirrhosis can slow its development. And for those who are severely ill, a liver transplant might be a second chance at life if they can commit to a healthier future. [1] Singal, A. K., Bataller, R., Ahn, J., Kamath, P. S., & Shah, V. H. (2018). ACG Clinical Guideline: Alcoholic Liver Disease. The American journal of gastroenterology, 113(2), 175–194. [2] Jophlin, L. L., Singal, A. K., Bataller, R., Wong, R. J., Sauer, B. G., Terrault, N. A., & Shah, V. H. (2024). ACG Clinical Guideline: Alcohol-Associated Liver Disease. The American journal of gastroenterology, 119(1), 30–54.
Los Angeles Times
08-04-2025
- Health
- Los Angeles Times
Hepatitis D: A Deeper Look at the Most Severe Viral Hepatitis
Hepatitis D, also called HDV infection, is widely known as the toughest form of viral hepatitis. Although not as famous as some other liver diseases, its impact can be devastating for those who get infected. The big twist with hepatitis D is that it depends on another virus—hepatitis B—to survive and multiply. In other words, you need to be infected with hepatitis B virus (HBV) first, or at the same time, for HDV to become active [1, 7]. This can happen when someone catches both HBV and HDV at once (coinfection), or when HDV strikes later if a person is already living with chronic HBV (superinfection). Table of Contents HDV is an unusual type of virus, sometimes referred to as a defective RNA viroid. By itself, it can't do much. It actually relies on the hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) to make new copies. Because of this special arrangement, HDV gets passed along the same routes as HBV, mainly through contact with infected blood—like sharing contaminated needles or receiving tainted blood products [4, 8]. Vaccination against hepatitis B virus (HBV) is crucial as it effectively prevents hepatitis D infection by eliminating the necessary environment for HDV replication. Scientists have found eight genotypes, or strains, of HDV. Different genotypes are common in different places. Some of these strains can lead to worse complications, including faster liver damage, while others seem milder. But no matter which genotype a person has, any form of HDV infection can cause more harm to the liver than HBV alone ([2]). Hepatitis D exists worldwide but tends to show up more often in specific groups. The hepatitis delta virus (HDV) is transmitted primarily through contact with infected blood, similar to hepatitis B virus (HBV). People who inject drugs face a high risk, partly because of needle sharing. Additionally, folks who come from regions where hepatitis D is widespread might bring the virus with them, possibly spreading it to new locations. Figuring out exactly how many people have HDV can be tricky. Some studies rely on small groups, others use different tests, and that causes confusion about the true numbers [6]. However, experts estimate it may range anywhere from 12 to 72 million people globally. Compared to an HBV infection by itself, HDV can cause: Chronic infections with HDV significantly increase the risk of liver failure, cirrhosis, and liver cancer. Because HDV often speeds up these serious complications, people who have both HBV and HDV need to keep a close eye on their health to catch any warning signs early. Spotting HDV can be complicated. One reason is that many labs worldwide don't always have the specialized tests to detect it. Plus, in the early stages of infection, HDV might not appear in standard bloodwork. All of this makes it tough to get a quick diagnosis. Despite these hurdles, it's vital to find HDV as soon as possible, since proper diagnosis can help prevent severe liver problems later [7]. Early detection of chronic infections is crucial to prevent severe liver complications and improve patient outcomes. Doctors have used pegylated interferon-α (IFN-α) for a while to tackle HDV, but it doesn't always work well. Many patients deal with relapses after treatment, and side effects can be rough [5]. Effective management of chronic infection with HDV is essential to reduce the risk of severe liver disease and improve long-term health outcomes. Several new therapies are under study and, though still in development, they bring hope for people battling chronic HDV: These medications could transform how we care for people infected with hepatitis D, offering better outcomes and fewer complications. Because HDV relies on HBV, stopping the spread of HBV and preventing hepatitis B infection in the first place is the best way to guard against HDV. Some core prevention steps include: Hepatitis D is often called the toughest type of viral hepatitis for good reason. The complications of hepatitis D, including severe liver diseases and liver failure, underscore the need for early diagnosis and effective treatment. It makes hepatitis B more severe and can rapidly push the liver toward dangerous complications. Yet, thanks to ongoing research, there are more solutions today than ever before. Groundbreaking therapies, improved understanding of the virus, and broader vaccination programs offer new ways to beat HDV. Still, major hurdles remain. It's important to encourage wider access to HBV vaccination and better testing to catch HDV sooner. Ongoing studies on therapies like bulevirtide and lonafarnib could pave the way for safer and more effective treatment strategies. By raising global awareness and combining prevention with medical innovation, we stand a real chance of halting the harmful effects of HDV once and for all. [1] Menegale, F., Manica, M., Zardini, A., Guzzetta, G., Marziano, V., d'Andrea, V., Trentini, F., Ajelli, M., Poletti, P., & Merler, S. (2023). Evaluation of Waning of SARS-CoV-2 Vaccine-Induced Immunity: A Systematic Review and Meta-analysis. JAMA network open, 6(5), e2310650. [2] Wedemeyer, H., & Manns, M. P. (2010). Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nature reviews. Gastroenterology & hepatology, 7(1), 31–40. [3] Yardeni, D., Heller, T., & Koh, C. (2022). Chronic hepatitis D-What is changing?. Journal of viral hepatitis, 29(4), 240–251. [4] Rizzetto M. (2015). Hepatitis D Virus: Introduction and Epidemiology. Cold Spring Harbor perspectives in medicine, 5(7), a021576. [5] Da, B. L., Heller, T., & Koh, C. (2019). Hepatitis D infection: from initial discovery to current investigational therapies. Gastroenterology report, 7(4), 231–245. [6] Post, Z., & Reau, N. (2023). What Is the Real Epidemiology of Hepatitis D Virus and Why so Many Mixed Messages?. Clinics in liver disease, 27(4), 973–984. [7] Lampertico, P., Degasperi, E., Sandmann, L., Wedemeyer, H., & Delta Cure 2022 Working Group (2023). Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022. JHEP reports : innovation in hepatology, 5(9), 100818. [8] Pascarella, S., & Negro, F. (2011). Hepatitis D virus: an update. Liver international : official journal of the International Association for the Study of the Liver, 31(1), 7–21. [9] Mentha, N., Clément, S., Negro, F., & Alfaiate, D. (2019). A review on hepatitis D: From virology to new therapies. Journal of advanced research, 17, 3–15. [10] Farci, P., & Niro, G. A. (2012). Clinical features of hepatitis D. Seminars in liver disease, 32(3), 228–236.
